Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate to Severe Atopic Dermatitis

NCT07502222 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT07502222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07502222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
Akeso
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 7, 2026
Completion date
January 10, 2028
Enrollment
168 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

moderate-to-severe atopic dermatitis